Potential predictive factors for response to weekly paclitaxel treatment in patients with metastatic breast cancer
Makaleler > Tam Makale · 2005
Yazarlar: C SEZGIN, BÜLENT KARABULUT, RÜÇHAN USLU, Ulus Ali ŞANLI, G GOKSEL, Osman ZEKİOĞLU, N OZDEMIR, Erdem GÖKER
JOURNAL OF CHEMOTHERAPY, SCI Expanded İndekslerine Giren Dergi, Uluslararası, 2005, cilt 17, ss 96-103
Özet
The authors compare results obtained from weekly paclitaxel treatment in advanced breast cancer patients with biological and clinical prognostic factors. Expression of c-erbB-2, Ki-67, p53 and hormone receptors (HR) was examined by immunohistochemistry in samples of breast tissue from 30 patients. Univariate analysis showed that Ki-67 positivity and low performance status (PS) were associated with poor outcome (P < 0.05). We observed that expression of p53 and c-erbB-2 did not have any negative effect on response to chemotherapy and survival. HR-negative patients had better response and slightly statistically significant overall survival (OS) rates compared to HR-positive patients (P > 0.05). In a multivariate analysis low PS was the only significant predictor of shorter survival (P < 0.05). In conclusion, while the expression of p53 and c-erbB-2 did not have any effect on treatment results, negative Ki-67 expression and negative HR status were associated with better OS in this patient population. PS was the only significant predictor for OS.